dual GSK3-beta/tau aggregation inhibitors (IRCCS)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namedual GSK3-beta/tau aggregation inhibitors (IRCCS)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMicrotubule-associated protein tau inhibitorsGlycogen synthase kinase-3 beta inhibitors
TargetsGlycogen synthase kinase-3 betaMicrotubule-associated protein tau
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A